DK4034122T3 - Fremgangsmåder til behandling af hyperfenylalaninæmi - Google Patents

Fremgangsmåder til behandling af hyperfenylalaninæmi

Info

Publication number
DK4034122T3
DK4034122T3 DK20789788.5T DK20789788T DK4034122T3 DK 4034122 T3 DK4034122 T3 DK 4034122T3 DK 20789788 T DK20789788 T DK 20789788T DK 4034122 T3 DK4034122 T3 DK 4034122T3
Authority
DK
Denmark
Prior art keywords
methods
hyperphenylalaninemia
treating
treating hyperphenylalaninemia
Prior art date
Application number
DK20789788.5T
Other languages
English (en)
Inventor
Niel Smith
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72827023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4034122(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Application granted granted Critical
Publication of DK4034122T3 publication Critical patent/DK4034122T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK20789788.5T 2019-09-25 2020-09-25 Fremgangsmåder til behandling af hyperfenylalaninæmi DK4034122T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
DK4034122T3 true DK4034122T3 (da) 2025-09-15

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20789788.5T DK4034122T3 (da) 2019-09-25 2020-09-25 Fremgangsmåder til behandling af hyperfenylalaninæmi

Country Status (23)

Country Link
US (1) US20220362249A1 (da)
EP (1) EP4034122B1 (da)
JP (2) JP7661315B2 (da)
KR (1) KR20220070477A (da)
CN (1) CN114650825A (da)
AU (1) AU2020353676B2 (da)
BR (1) BR112022003719A2 (da)
CA (1) CA3150003A1 (da)
DK (1) DK4034122T3 (da)
ES (1) ES3041002T3 (da)
FI (1) FI4034122T3 (da)
HR (1) HRP20251268T1 (da)
HU (1) HUE073483T2 (da)
IL (1) IL291565B1 (da)
JO (1) JOP20220042A1 (da)
LT (1) LT4034122T (da)
MX (1) MX2022003585A (da)
PL (1) PL4034122T3 (da)
PT (1) PT4034122T (da)
RS (1) RS67295B1 (da)
SI (1) SI4034122T1 (da)
SM (1) SMT202500493T1 (da)
WO (1) WO2021062264A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩

Also Published As

Publication number Publication date
MX2022003585A (es) 2022-04-19
ES3041002T3 (en) 2025-11-06
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
BR112022003719A2 (pt) 2022-05-31
EP4034122A1 (en) 2022-08-03
FI4034122T3 (fi) 2025-10-08
RS67295B1 (sr) 2025-11-28
HRP20251268T1 (hr) 2025-12-05
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
SMT202500493T1 (it) 2026-01-12
HUE073483T2 (hu) 2026-01-28
AU2020353676B2 (en) 2026-04-30
JP2025111476A (ja) 2025-07-30
IL291565B1 (en) 2026-04-01
SI4034122T1 (sl) 2025-12-31
KR20220070477A (ko) 2022-05-31
US20220362249A1 (en) 2022-11-17
CN114650825A (zh) 2022-06-21
EP4034122B1 (en) 2025-08-13
CA3150003A1 (en) 2021-04-01
PL4034122T3 (pl) 2026-01-26
IL291565A (en) 2022-05-01
AU2020353676A1 (en) 2022-04-14
LT4034122T (lt) 2025-11-10
JP7661315B2 (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
DK3501542T3 (da) Esketamin til behandling af depression
DK3322722T3 (da) Midler, anvendelser og fremgangsmåder til behandling af synukleinopati
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3559265T3 (da) Fremgangsmåde til behandling af polynukleotider
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3582853T3 (da) Cykliske dinukleotidforbindelser til behandling af cancer
DK3478286T3 (da) Fremgangsmåder til behandling af ovariecancer
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3728585T3 (da) Hidtil ukendte fremgangsmåder til fremstilling af oligonukleotider
DK3303618T3 (da) Fremgangsmåder til prognose af prostatacancer
DK3283136T4 (da) Hydrofile belægninger og fremgangsmåder til dannelse af samme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
IL285110A (en) Methods of treating multiple myeloma
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
DK3307682T3 (da) Fremgangsmåde til biologisk rensning af spildevand
DK3661562T3 (da) Fremgangsmåde til konjugation af cys-mabs
DK3393468T3 (da) Fremgangsmåder til behandling af en immundefektsygdom
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3952858T3 (da) Fremgangsmåde til behandling af tumorer
DK3661510T3 (da) Fremgangsmåder til behandling af adfærdsændringer